Pharming reports Q3 2023 financial results, incl. increased Ruconest revenue

Pharming Group reports third quarter 2023 financial results, including increased Ruconest revenue

Pharming Group presents its preliminary, unaudited financial report for the three months ended September 30, 2023.

The company reported 23% revenue growth in the third quarter of 2023, versus the same period last year. Pharming considered this growth attributable to increased Ruconest revenue, coupled with initial Joenja revenues of US$6.5 million.

Sijmen de Vries, Chief Executive Officer, comments: “Pharming delivered a strong third quarter, increasing quarterly revenues to US$66.7 million and putting the Company at US$164.1 million in revenues for the first nine months of the year. The 23% revenue growth seen in the third quarter of 2023, versus the same period last year, was attributable to increased Ruconest revenue, coupled with initial Joenja revenues of US$6.5 million.”

(Source: Pharming)